Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Viral Rhinotracheitis, S

Verify with FDA CVM →

387 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
387
Total Reports
78
Deaths Reported
2020.0%
Death Rate

Active Ingredients

Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Viral Rhinotracheitis, S

Administration Routes

SubcutaneousSubconjunctivalIntramuscular

Species Affected

Cat 386
Dog 1

Most Affected Breeds

Domestic Shorthair 244
Domestic Longhair 40
Domestic Mediumhair 23
Cat (other) 16
Siamese 11
Ragdoll 9
Maine Coon 7
Bengal 6
Cat (unknown) 6
Sphynx 4

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 159
Fever 151
Vomiting 104
Anorexia 83
Not eating 72
Lethargy (see also Central nervous system depression in Neurological) 52
Weight loss 47
Decreased appetite 44
Death 39
Lack of efficacy - NOS 38
Dehydration 37
Anaemia NOS 36

Outcome Breakdown

Ongoing
207 (52.9%)
Recovered/Normal
91 (23.3%)
Died
43 (11.0%)
Euthanized
36 (9.2%)
Outcome Unknown
14 (3.6%)

Data Summary

Metric Value
Total adverse event reports 387
Reports involving death 78
Case-fatality rate (reported events) 2020.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Viral Rhinotracheitis, S Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 387 adverse event reports referencing Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Viral Rhinotracheitis, S, including 78 reports in which the animal died — a 2020.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Viral Rhinotracheitis, S. Reported administration routes include Subcutaneous, Subconjunctival, Intramuscular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Viral Rhinotracheitis, S reports are Cat (386 reports), Dog (1 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (244), Domestic Longhair (40), Domestic Mediumhair (23) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Viral Rhinotracheitis, S are Lethargy (see also Central nervous system depression in 'Neurological') (159), Fever (151), Vomiting (104), Anorexia (83). Of the 391 reports with a coded outcome, Ongoing is the leading category at 52.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Feline Calicivirus, Strain F-9, Passage 7, Lot A;Feline Viral Rhinotracheitis, S.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial